期刊
INFLAMMATORY BOWEL DISEASES
卷 29, 期 5, 页码 830-833出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izac164
关键词
ulcerative colitis; Crohn's disease; inflammatory bowel disease; ustekinumab; loss of response; dose escalation; optimization
In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients for up to 24 months.
Lay Summary In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients for up to 24 months.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据